Publication:
Early intravenous nitroglycerin use in prehospital setting and in the emergency department to treat patients with acute heart failure: Insights from the EAHFE Spanish registry

dc.contributor.authorMiro, Oscar
dc.contributor.authorLlorens, Pere
dc.contributor.authorFreund, Yonathan
dc.contributor.authorDavison, Beth
dc.contributor.authorTakagi, Koji
dc.contributor.authorHerrero-Puente, Pablo
dc.contributor.authorJacob, Javier
dc.contributor.authorMartin-Sanchez, Francisco Javier
dc.contributor.authorGil, Victor
dc.contributor.authorRosselló, Xavier
dc.contributor.authorAlquezar-Arbe, Aitor
dc.contributor.authorJimenez-Fabrega, Francesc X
dc.contributor.authorMasip, Josep
dc.contributor.authorMebazaa, Alexandre
dc.contributor.authorCotter, Gad
dc.contributor.authorEAHFE Res Group
dc.date.accessioned2024-09-18T06:42:20Z
dc.date.available2024-09-18T06:42:20Z
dc.date.issued2021-12-01
dc.description.abstractBackground and objective: Although recommended for the treatment of acute heart failure (AHF), the use of intravenous (IV) nitroglycerin (NTG) is supported by scarce and contradicting evidence. In the current analysis, we have assessed the impact of IV NTG administration by EMS or in emergency department (ED) on outcomes of AHF patients. Methods: We analyze AHF patients included by 45 hospitals that were delivered to ED by EMS. Patients were grouped according to whether treatment with IV NTG was started by EMS before ED admission (preED-NTG), during the ED stay (ED-NTG) or were untreated with IV NTG (no-NTG, control group). In-hospital, 30-day and 365-day all-cause mortality, prolonged hospitalization (>7 days) and 90-day post-discharge combined adverse events (ED revisit, hospitalization or death) were compared in EMS-NTG and ED-NTG respect to control group. Results: We included 8424 patients: preED-NTG = 292 (3.5%), ED-NTG = 1159 (13.8%) and no-NTG = 6973 (82.7%). preED-NTG group had the most severely decompensated cases of AHF (p < 0.001) but it had lower inhospital (OR = 0.724, 95%CI = 0.459-1.114), 30-day (HR = 0.818, 0.576-1.163) and 365-day mortality (HR = 0.692, 0.551-0.869) and 90-day post-discharge events (HR = 0.795, 0.643-0.984) than control group. ED-NTG group had mortalities similar to control group (in-hospital: OR = 1.164, 0.936-1.448; 30-day: HR = 0.980, 0.819-1.174; 365-day: HR = 0.929, 0.830-1.039) but significantly decreased 90-day post-discharge events (HR = 0.870, 0.780-0.970). Prolonged hospitalization rate did not differ among groups. Five different analyses confirmed these findings. Conclusions: Early prehospital IV NTG administration was associated with lower mortality and post-discharge events, while IV NTG initiated in ED only improved post-discharge event rate. Further studies are needed to assess the role of early prehospital administration of IV NTG to patients with AHF.en
dc.description.sponsorshipThis study was partially supported by grants from the Instituto de Salud Carlos III supported with funds from the Spanish Ministry of Health and FEDER (PI15/01019, PI15/00773, PI18/00393, PI18/00456) and Fundació La Marato de TV3 (2015/2510). The Emergencies: Processes and Pathologies research group of the IDIBAPS receives financial support from the Catalonian Government for Consolidated Groups of Investigation (GRC 2009/1385, 2014/0313, and 2017/1424). We thank Alicia Diaz for her professionalism in data management.es_ES
dc.format.page127-134es_ES
dc.format.volume344es_ES
dc.identifier.citationMiro O, Llorens P, Freund Y, Davison B, Takagi K, Herrero-Puente P, et al. Early intravenous nitroglycerin use in prehospital setting and in the emergency department to treat patients with acute heart failure: Insights from the EAHFE Spanish registry. Int J Cardiol. 2021 Dec 1;344:127-34.en
dc.identifier.doi10.1016/j.ijcard.2021.09.031
dc.identifier.e-issn1874-1754es_ES
dc.identifier.issn0167-5273
dc.identifier.journalInternational Journal of Cardiologyes_ES
dc.identifier.otherhttps://hdl.handle.net/20.500.13003/19550
dc.identifier.pubmedID34543690es_ES
dc.identifier.puiL2014723315
dc.identifier.scopus2-s2.0-85115644341
dc.identifier.urihttps://hdl.handle.net/20.500.12105/23192
dc.identifier.wos757375800024
dc.language.isoengen
dc.publisherElsevier
dc.relation.publisherversionhttps://dx.doi.org/10.1016/j.ijcard.2021.09.031en
dc.rights.accessRightsopen accessen
dc.rights.licenseAttribution 4.0 International*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subjectAcute heart failure
dc.subjectNitrates
dc.subjectNitroglycerine
dc.subjectOutcome
dc.subjectMortality
dc.subject.decsInsuficiencia Cardíaca*
dc.subject.decsHumanos*
dc.subject.decsNitroglicerina*
dc.subject.decsCuidados Posteriores*
dc.subject.decsServicio de Urgencia en Hospital*
dc.subject.decsAlta del Paciente*
dc.subject.decsEnfermedad Aguda*
dc.subject.decsSistema de Registros*
dc.subject.meshAftercare*
dc.subject.meshEmergency Service, Hospital*
dc.subject.meshAcute Disease*
dc.subject.meshNitroglycerin*
dc.subject.meshHumans*
dc.subject.meshRegistries*
dc.subject.meshPatient Discharge*
dc.subject.meshHeart Failure*
dc.titleEarly intravenous nitroglycerin use in prehospital setting and in the emergency department to treat patients with acute heart failure: Insights from the EAHFE Spanish registryen
dc.typeresearch articleen
dspace.entity.typePublication
relation.isPublisherOfPublication7d471502-7bd5-4f7a-90a4-8274382509ef
relation.isPublisherOfPublication.latestForDiscovery7d471502-7bd5-4f7a-90a4-8274382509ef

Files